<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865277</url>
  </required_header>
  <id_info>
    <org_study_id>STR-INDIRA-MISO-2014</org_study_id>
    <nct_id>NCT03865277</nct_id>
  </id_info>
  <brief_title>Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging</brief_title>
  <acronym>INDIRA-MISO</acronym>
  <official_title>Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging: Multi-center, Randomized Phase-II-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial evaluates the value of radiation dose escalation based on Hypoxia detection by
      18F_misonidazole Positron Emission Tomography (18F-MISO-PET) for primary radiochemotherapy of
      head and neck squamous cell carcinoma. Patients negative for human papillomavirus (HPV) and
      with hypoxic tumours after 2 weeks of radiochemotherapy are randomized to completion of
      standard radiochemotherapy or radiochemotherapy with escalated radiation dose. An additional
      interventional arm includes a carbon ion boost. HPV positive tumours can be included in a
      control arm. Primary endpoint is local tumour control 2 years after radiochemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous preclinical data and a prospective validated patient cohort have shown that patients
      with head and neck squamous cell carcinoma, whose tumours are hypoxic after 2 weeks of
      primary radiochmeotherapy, have a significantly lower chance of locoregional tumour control.
      The multi-center trial evaluates the value of radiation dose escalation based on hypoxia
      detection by 18F_misonidazole Positron Emission Tomography (18F-MISO-PET) for primary
      radiochemotherapy of head and neck squamous cell carcinoma. Patients negative for human
      papillomavirus (HPV) and with hypoxic tumours after 2 weeks of radiochemotherapy are
      randomized to completion of standard radiochemotherapy (70 Gy) or radiochemotherapy with
      escalated radiation dose (77 Gy). An additional interventional arm includes a carbon ion
      boost to 77 Gy. HPV positive tumours can be included in a control arm. Primary endpoint is
      local tumour control 2 years after radiochemotherapy. Secondary endpoints include acute and
      late toxicity (CTCAE 5.0), regional tumor control, overall survival, disease free survival,
      distant metastases, kinetics analysis of dynamic FMISO-PET scans, Quality of life (QoL). The
      hypothesis is that local tumour control 2 years after radiochemotherapy is higher in the dose
      escalated compared to the control arm.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local tumour control</measure>
    <time_frame>Local tumor control 2 years after end of treatment</time_frame>
    <description>Local tumour control (MRI, CT, PET or clinical evaluation) in the randomized dose-escalated arm compared to the randomized non dose escalated arm (arms 1 and 2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>late toxicity</measure>
    <time_frame>30 days to 2 years after radiochemotherapy</time_frame>
    <description>late toxicity based on CTCAE 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>2 years after radiochemotherapy</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life EORTC QLQ-C30/HN-35</measure>
    <time_frame>regularly up to 2 years after radiochemotherapy</time_frame>
    <description>EORTC-QLQ (C30 and HN-35) Sheets (General for tumour diseases and specific for head and neck cancer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>during treatment and up to 30 days after radiochemotherapy</time_frame>
    <description>acute toxicity based on CTCAE 5.0</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">345</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>standard radiochemotherapy, hypoxic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to standard radiation dose, 70 Gy standard radiochemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose-escalated radiochemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to escalated radiation dose, 77 Gy radiochemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>escalated radiochemoth., carbon boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, non-randomised arm (only possible in the trial center Heidelberg), 77 Gy radiochemotherapy (boost with carbon)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard radiochemotherapy, oxic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HPV (-), oxic in 18F-MISO PET after 2 weeks of radiochemotherapy, 70 Gy standard radiochemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard radiochemotherapy (70 Gy)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HPV (+), HPV positive patients will get the same imaging and clinical examinations as HPV negative patients. This measure is necessary to further elucidate the prognostic role of hypoxia and HPV status and their correlation, the information will be important for consecutive clinical trials. 70 Gy standard radiochemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>standard radiochemotherapy or dose-escalated radiochemotherapy</intervention_name>
    <description>Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).
Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if &quot;hypoxic&quot; and randomized to the intervention arm, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases &gt; 2 cm.
Radiotherapy is always applied with 5 fractions per week.</description>
    <arm_group_label>dose-escalated radiochemotherapy</arm_group_label>
    <arm_group_label>escalated radiochemoth., carbon boost</arm_group_label>
    <arm_group_label>standard radiochemotherapy (70 Gy)</arm_group_label>
    <arm_group_label>standard radiochemotherapy, hypoxic</arm_group_label>
    <arm_group_label>standard radiochemotherapy, oxic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: older than 18 years

          -  WHO (ECOG) performance status 0-2

          -  Histological proven HNSCC

          -  HPV negative tumors or HPV positive tumors

          -  Stage III, IVA or IVB HNSCC according to UICC and AJCC guidelines

          -  Tumor classified as irresectable or patient inoperable or patient refused surgery

          -  Tumor extension and localization suitable for radiochemotherapy with curative intent

          -  Simultaneous standard chemotherapy with cisplatin applicable (no contra-indications)

          -  Dental examination and -treatment before start of therapy

          -  For women with childbearing potential and men in reproductive ages adequate
             contraception.

          -  Ability of subject to understand character and individual consequences of the clinical
             trial

          -  Written informed consent (must be available before enrolment in the trial)

        Exclusion Criteria:

          -  Refusal of the patients to take part in the trial

          -  Presence of distant metastases (UICC stage IVC)

          -  Previous radiotherapy in the head and neck region

          -  Second malignancy that is likely to require treatment during the trial intervention or
             follow-up period or that, in the opinion of the physician, has a considerable risk of
             recurrence or metastases within the follow-up period

          -  Serious disease or medical condition with life expectancy of less than one year

          -  Participation in competing interventional trial on cancer treatment

          -  Patients who are not suitable for radiochemotherapy

          -  Pregnant or lactating women

          -  Patients not able to understand the character and individual consequences of the trial

          -  Nasopharyngeal Carcinomas
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mechthild Krause, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology, German Consortium for Translational Cancer Research (DKTK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mechthild Krause, Prof. Dr.</last_name>
    <phone>+49 351 458 2238</phone>
    <email>mechthild.krause@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Esther Troost, Prof.Dr.Dr.</last_name>
    <phone>+49 351 458 7433</phone>
    <email>esther.troost@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Radiation Oncology, Vienna General Hospital (AKH)</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Faculty, Albert-Ludwigs-Universität Freiburg, Department of Radiation Oncology</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Grosu Anca, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Oncology Heidelberg University Medical School</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Jürgen Debus, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Jürgen Debus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Oncology</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72016</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Daniel Zips, Prof. Dr.</last_name>
      <phone>+49 7071/29-8 21 65</phone>
      <email>ROInfo@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Zips</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mechthild Krause</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Mechthild Krause, Prof. Dr.</last_name>
      <phone>+493512238</phone>
      <email>str.studien@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Facoltà di Medicina e Chirurgia - Università Cattolica S.C. Istituto di Radiologia, Radioterapia 1</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karol-Marcinkowski Medical University of Poznan, Department of Radiation Oncology, Greater Poland Cancer Center, Department of Radiotherapy</name>
      <address>
        <city>Poznań</city>
        <zip>61-866</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>May 31, 2019</last_update_submitted>
  <last_update_submitted_qc>May 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Mechthild Krause</investigator_full_name>
    <investigator_title>Director of the Department of Radiotherapy and Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Head and neck cancer</keyword>
  <keyword>radiochemotherapy</keyword>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

